Day One Biopharmaceuticals, Inc.(DAWN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Day One Biopharmaceuticals, Inc. (DAWN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DAWN at 26.0/100 on a 32-signal composite quality model, placing it at rank #2,641 of 2,961 stocks — the bottom half of the AI-ranked universe. DAWN scores in the top quartile across revenue growth (81.4). Areas of concern include profitability (0.1) and institutional flow (2.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Day One Biopharmaceuticals, Inc. reports quarterly revenue of $53.7M, net income of $-107.2B, free cash flow of $-14.1M. Top institutional holders of DAWN by reported 13-F value include BlackRock, GLAZER CAPITAL, FIL Ltd, based on the most recent SEC filings. DAWN trades on the Nasdaq exchange and files with the SEC under CIK 1845337. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DAWN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Day One Biopharmaceuticals, Inc. directly from SEC EDGAR.